Recombinant activated protein C treatment improves tissue perfusion and oxygenation in septic patients measured by near-infrared spectroscopy

Table 2 Cardiac index, ITBVI, norepinephrine dose, and dobutamine dose before, during, and after rh-aPC treatment

	T0	T1a	T1b	T1c	T1d	T2
rh-aPC group
Cardiac index	4.6 ± 1.3	4.6 ± 1.3	3.8 ± 0.7	4.1 ± 1.7	4.0 ± 1.0	4.1 ± 0.7
ITBVI	883 ± 207	874 ± 189	884 ± 203	922 ± 223	876 ± 213	872 ± 176
Norepinephrine*	0.22 (0.16 to 0.35)	0.22 (0.15 to 0.38)	0.22 (0.14 to 0.34)	0.22 (0.11 to 0.24)	0.17 (0.02 to 0.23)	0.14 (0.01 to 0.21)
Dobutamine*	3.4 (1 to 4.8)	2.8 (1 to 3.25)	2.1 (0 to 3.4)	2.1 (0 to 3.1)	2 (0 to 3.1)	2 (0 to 3.1)
Control group
Cardiac index	4.2 ± 0.6	4.1 ± 1.1	4.3 ± 0.7	4.2 ± 0.5	4.1 ± 0.8	4.1 ± 0.7
ITBVI	892 ± 249	894 ± 211	926 ± 208	897 ± 265	913 ± 280	891 ± 260
Norepinephrine	0.17 (0.06 to 0.37)	0.37 (0.11 to 0.5)	0.27 (0.11 to 0.37)	0.27 (0.11 to 0.37)	0.37 (0.11 to 0 to 4)	0.37 (0.11 to 0.4)
Dobutamine	4.2 (0 to 5.3)	0 (0 to 3.7)	0 (0 to 3.7)	2.3 (0 to 3.7)	2.3 (0 to 3.7)	2.3 (0 to 3.7)

Data are presented as the mean ± standard deviation or as the median (first to third interquartile range). Data were collected before (T0), during (24 hours (T1a), 48 hours (T1b), 72 hours (T1c), and 96 hours (T1d)), and 6 hours (T2) after recombinant activated protein C (rh-aPC) treatment (that is, 102 hours from T0). ITBVI, intrathoracic blood volume index. *P < 0.01, Friedman test in the rh-aPC group.

ISSN: 1364-8535